Kura Oncology CEO Troy Wilson Buys 100,000 Shares

What Happened
Troy Edward Wilson, President and CEO (also a director) of Kura Oncology, acquired 100,000 shares in open-market purchases on August 17, 2026. The weighted average purchase price was $11.12 per share for a total cash outlay of $1,112,000. This was a purchase (potentially interpreted as a bullish insider buy) rather than a sale.

Key Details

• Transaction date: 2026-08-17 (reported on Form 4 with period of report 2026-08-17)
• Transaction type: Open market purchase (Code P)
• Shares acquired: 100,000 shares
• Price: Weighted average $11.12 per share; execution prices ranged $10.87–$11.31 (see footnote)
• Total value: $1,112,000
• Shares owned after transaction: Not disclosed in the excerpt of the filing
• Footnote: F1 states the transaction was executed in multiple trades at prices $10.87–$11.31 and the reported price is the weighted average; reporting person will provide full trade details upon request.
• Filing timeliness: Reported on the same date (no late filing indicated)

Context
Open-market purchases by executives are often viewed as a positive signal because they involve the insider using personal funds to buy company stock; however, filings are factual records and do not explain motivations. There were no derivative exercises, gifts, or tax-withholding actions noted in this filing excerpt.